drugset / Trial / NCT00021697

Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS

NCT00021697

Phase 3 Completed 100 enrolled Avanir Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare and evaluate the safety of AVP-923 (dextromethorphan/quinidine) for the treatment of emotional lability in ALS patients.

Timeline

Start
2001-01
Primary completion
2002-04
Completion
2002-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dextromethorphan Unknown 30 mg
Subject Quinidine Small molecule 30 mg